Radical enhancements for cognition or longevity will likely be adopted by healthy people only after they are first developed and FDA-approved as therapies for specific diseases, like Alzheimer's. Competitive pressures will then drive widespread use, similar to obesity drugs.

Wonder Health operates a high-end lab not as its primary business, but as a research engine. By collecting unique, cross-disciplinary data from 100 "guinea pigs," it aims to uncover patterns and insights that can be developed into scalable health products for a broad audience.

General Catalyst's CEO highlights a core flaw in healthcare: insurance providers don't reimburse for longevity or preventative care because customers frequently switch plans, preventing insurers from capturing long-term ROI. The first company to solve this misalignment and make longevity "financeable" will unlock a massive market.

While the wealthy can access expensive protocols involving diagnostics and lifestyle optimization, these offer only marginal benefits. True, effective longevity will not come from this but from validated, mass-produced biotech drugs that target the core mechanisms of aging.

Prestigious health systems like Weill Cornell and Mayo Clinic are offering longevity programs priced up to $45,000 annually. These services operate as direct cash-pay models, allowing hospitals to circumvent insurance friction while tapping strong consumer demand to improve their bottom lines.

Function Health provides comprehensive lab testing with over 160 biomarkers, which would typically cost $15,000, for a $365 annual membership. This business model makes high-end, data-driven preventative care accessible to a much broader audience beyond the wealthy who can afford traditional concierge doctors.

Anti-aging treatments will pay for themselves by eliminating the enormous medical costs of late-life health problems. This creates a powerful economic imperative for governments to ensure universal access, countering the common fear that such therapies will only be available to the wealthy.

Extensive diagnostic batteries mostly confirmed baseline health rather than uncovering critical new diagnoses, yet the experience still motivated healthier habits. Patients are primarily paying thousands of dollars for extended clinician attention and multi-specialist lifestyle guidance that typical primary care appointments cannot provide.

Andrew Huberman predicts GLP-1 drugs, accessed via compounding pharmacies and gray markets, will become so ubiquitous that being a healthy weight will no longer signal extreme discipline. This mirrors how auto loans and leases made luxury cars accessible to the masses, changing their social signaling value.